News

A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

In a late-breaking presentation at ASGCT 2022, investigators shared preclinical results of a gene-editing strategy that seeks to reactivate developmentally silenced fetal hemoglobin (HbF, α2γ2) in order to replace defective sickle hemoglobin (HbS, α2βS2).

Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.

Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.

Patients with IBD are often at an increased risk of developing NAFLD.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.

Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.

Post-treatment, data show molecular age remained significantly greater than chronological age at a median difference of 18.6 years.

The data presented at DDW show similar safety and efficacy for the 2 treatments.

Montefiore psychiatry chair Jonathan Alpert, MD, PhD, discusses suggested updates to the DSM-5—with consideration to social determinants and patient-reported functioning.

Recurrence commonly occurred during the first 2 weeks regardless of treatment.

Linda Chokroverty, MD, discusses the role psychiatrists play in managing the mental health effects of disasters, and how children specifically may be impacted.

Both post-transplant PPI and histamine-2 receptor antagonist use were independently associated with reduced risk of 1-year mortality.

A pair of psychiatrists discuss how climate change and other social determinants of health are affecting the mental wellbeing of indigenous people.

DASH diet was inversely associated with NAFLD risk, independent of BMI changes.

The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.

There remains a need for longer-term observational studies comparing the 2 treatments.

It takes even more than a village to provide the comprehensive care needed for aging, neurocognitive patients, says Rajesh R. Tampi, MD, MS.

A 6-year mirror analysis of risperidone, once-monthly paliperidone palmitate or once-monthly aripiprazole concludes suggesting the regimens may serve as an alternative to clozapine.

Sarcoidosis expert Dr. Wonder Drake got into the field after diagnosing a patient with the disease early in her career. In this interview she explains the best way to approach a suspected case of sarcoidosis.

Dupilumab is the first treatment in the US indicated for adults and pediatric patients over 12 years with EoE.

Guselkumab was effective in patients with previous biologic therapies, comorbidities or psoriasis manifestation in difficult-to-treat areas.

Despite being one of the most common dermatologic conditions, the etiology of chronic pruritis is still unknown, and conventional medication may not always result in a good therapeutic response.

Dr. Carolyn Rowley talks about the Cayenne Wellness Center's mental health initiative for individuals with sickle cell disease and shares the story of one of her first patients.

A significant decrease in SII, SIRI, CRP, and UAS-7 was observed in the third month of omalizumab treatment, and the responder groups at 3 and 6 months of treatment had significantly higher baseline SII and SIRI levels than non-responders.

In this episode of Diabetes Dialogue, hosts Drs. Isaacs and Bellini take a deep dive into the tirzepatide approval, including discussions around the mechanism of action, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hosts recap their experiences from AACE 2022, which saw the release of new guidelines for NAFLD.

The bioactive triterpenoid saponin was associated with edema in treated patients.